BEMPEGALDESLEUKIN for Malignant melanoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 30 adverse event reports in the FDA FAERS database where BEMPEGALDESLEUKIN was used for Malignant melanoma.
Most Reported Side Effects for BEMPEGALDESLEUKIN
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Acute kidney injury | 9 | 5.2% | 1 | 8 |
| Cerebrovascular accident | 9 | 5.2% | 1 | 9 |
| Hypotension | 9 | 5.2% | 0 | 9 |
| Atrial fibrillation | 7 | 4.0% | 0 | 6 |
| Pyrexia | 7 | 4.0% | 1 | 7 |
| Malignant neoplasm progression | 6 | 3.5% | 4 | 5 |
| Eosinophilia | 5 | 2.9% | 0 | 5 |
| Pulmonary embolism | 5 | 2.9% | 2 | 5 |
Other Indications for BEMPEGALDESLEUKIN
Renal cell carcinoma (45)
Transitional cell carcinoma (26)
Non-small cell lung cancer (13)
Metastatic renal cell carcinoma (6)
Sarcoma (6)
Metastatic malignant melanoma (5)
Triple negative breast cancer (5)
Other Drugs Used for Malignant melanoma
NIVOLUMAB (10,599)
IPILIMUMAB (8,903)
DABRAFENIB (5,277)
TRAMETINIB DIMETHYL SULFOXIDE (3,841)
PEMBROLIZUMAB (3,261)
BINIMETINIB (2,613)
ENCORAFENIB (2,591)
VEMURAFENIB (2,548)
TRAMETINIB (1,448)
COBIMETINIB (1,324)